PRIDD vs RAJKA 2024 ISAD

Patient-Reported Impact of Dermatological Diseases (PRIDD) is a new and unique measure of the impact of dermatological diseases on the patient’s life and is the first dermatology-specific tool that is applicable to all skin conditions. No other dermatology tool has such broad applicability. PRIDD assesses four dimensions of impact: physical, psychological, life responsibilities and social impacts. PRIDD was developed using a scientifically rigorous and published methodology, resulting in the only dermatology-specific PROM that can be recommended for use according to the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) criteria. PRIDD was developed over seven years in partnership with Cardiff University, University of Hamburg, GlobalSkin and more than 5600 patients living with 90 different dermatological conditions from 96 countries. Each of the development phases of PRIDD have been published in reputable dermatology journals. It the first validated measure in dermatology developed with patients at every step of the process. To learn more about the development of the measure visit https://globalskin.org/research. The entire dermatology community – patients, clinicians, researchers, and pharmaceutical companies – can use PRIDD to better understand patient suffering thereby promoting improved patient-centered healthcare.

This year we chose the theme ‘Global Perspectives on Atopic Dermatitis: Uniting for a better Care’, and we are very pleased and proud that we are able to welcome world-renowned basic scientists and clinicians covering all aspects of atopic dermatitis, many of them pioneers in their field. Since Atopic Dermatitis is a global, frequent disease, we also sought to invite experts from WHO and all around the world to discuss how we can improve patient’s quality of life by providing and uniting for better treatments for all patients. One of the main subjects of this meeting will be the debilitating symptom of “pruritus (itching)”, its pathophysiology, assessment and treatment, because of its novel treatments, a very hot topic in dermatology and neuroimmunology. Here, we will explore where the future of Atopic Dermatitis therapy will go. The City of Doha is the capital of the State of Qatar and represents all the beauty and hospitality of the Arabian peninsula. Despite the astonishing natural and quite beauty of the desert, Qatar is a growing industrial modern country which attracts many tourists and families, as well as industry and universities. The venue of the meeting, the Sheraton hotel is located in the heart of the beautiful center of Doha, close to museums, cafes and beaches, which invite to relax during a pleasant Arabic winter enjoying culture and nature alike. For the first time in the Middle East, we have assembled an exciting program for scientists, clinicians, residents, students and industry partners alike, that will cover all aspects of Atopic Dermatitis research. Please join us for a special program in which you can experience in the best way possible, Arabic hospitality and make new friends. We are looking forward to welcoming you to Doha.